Relfydess presentations include two encore post-hoc subgroup analyses of pooled phase III READY program data in moderate-to-severe frown lines and crow’s feet. These data showed:


>98% and >88% investigator-assessed responder rates after one month of treatment in patients with frown lines and crow’s feet, respectively3

>24 weeks median time to return to baseline severity for both frown lines and crow’s feet, as assessed by both patients and investigators2


Additionally, new Relfydess data includes results from an in vivo head-to-head study of Relfydess and OnabotulinumtoxinA showing similar and limited levels of diffusion in a rat model.6

Together, these analyses provided further evidence to support Relfydess’ rapid onset and efficacy through six months regardless of previous neuromodulator treatment, robust
=*=*=*=*=*=
当前为第3/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页